Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

被引:92
|
作者
Devillier, Raynier [1 ]
Coso, Diane [1 ]
Castagna, Luca [1 ,2 ]
Rossi, Isabelle Brenot [3 ]
Anastasia, Antonella [2 ]
Chiti, Arturo [4 ]
Ivanov, Vadim [1 ]
Schiano, Jean Marc [1 ]
Santoro, Armando [2 ]
Chabannon, Christian [1 ,5 ,6 ]
Balzarotti, Monica [2 ]
Blaise, Didier [1 ,5 ,6 ]
Bouabdallah, Reda [1 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, Transplantat & Cell Therapy Program, F-13009 Marseille, France
[2] Ist Clin Humanitas, Humanitas Canc Ctr, Hematol Unit, Milan, Italy
[3] Inst J Paoli I Calmettes, Dept Nucl Med, F-13009 Marseille, France
[4] Ist Clin Humanitas, Humanitas Canc Ctr, Nucl Med Unit, Milan, Italy
[5] Inst J Paoli I Calmettes, INSERM, CBT 510, Ctr Invest Clin Biotherapie, F-13009 Marseille, France
[6] Univ Aix Marseille, Fac Med, Inst J Paoli I Calmettes, Marseille, France
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 07期
关键词
Hodgkin's lymphoma; PET; outcome; relapsed refractory; ASCT; HIGH-DOSE CHEMOTHERAPY; PROGNOSTIC-FACTORS; FDG-PET; DISEASE; MULTICENTER; FAILURE; SCORE;
D O I
10.3324/haematol.2011.056051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. Design and Methods We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. Results Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). Conclusions In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
引用
收藏
页码:1073 / 1079
页数:7
相关论文
共 50 条
  • [1] Pretransplantation Positron Emission Tomography Predicts Outcome Following Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
    Dulery, Remy
    Marjanovic, Zora
    Aoudjane, Malek
    Corre, Elise
    Lemonnier, Marie-Paule
    Vekhoff, Anne
    Coppo, Paul
    Mohty, Mohamad
    BLOOD, 2015, 126 (23)
  • [2] Outcome of gemcitabine-based salvage chemotherapy and autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma
    Kuruvilla, J.
    Nagy, T.
    Zadeh, S.
    Puig, N.
    Seshadri, T.
    Tsang, R.
    Keating, A.
    Crump, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 77 - 77
  • [3] Autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma
    Afonso, S.
    Carvalhais, I.
    Carneiro, A.
    Araujo, J.
    Principe, F.
    Guimaraes, J. E.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S440 - S441
  • [4] Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
    Moskowitz, Alison J.
    Yahalom, Joachim
    Kewalramani, Tarun
    Maragulia, Jocelyn C.
    Vanak, Jill M.
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    BLOOD, 2010, 116 (23) : 4934 - 4937
  • [5] Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma
    Hazar, Volkan
    Kesik, Vural
    Aksoylar, Serap
    Karakukcu, Musa
    Ozturk, Gulyuz
    Kupesiz, Alphan
    Atas, Erman
    Oniz, Haldun
    Kansoy, Savas
    Unal, Ekrem
    Tanyeli, Atila
    Erbey, Fatih
    Elli, Murat
    Tacyildiz, Nurdan
    Karasu, Gulsun Tezcan
    Kocak, Ulker
    Anak, Sema
    Bengoa, Sebnem Yilmaz
    Sezgin, Gulay
    Atay, Didem
    Unal, Emel
    Uygun, Vedat
    Kurucu, Nilgun
    Kaya, Zuhre
    Yesilipek, Akif
    PEDIATRIC TRANSPLANTATION, 2015, 19 (07) : 745 - 752
  • [6] Single Agent Gemcitabine As a Salvage Regimen in Patients with Relapsed/Refractory Hodgkin's Lymphoma after Autologous Stem Cell Transplantation
    Ozdemir, Evren
    Aslan, Alma
    Turker, Alev
    Barista, Ibrahim
    Kars, Ayse
    BLOOD, 2015, 126 (23)
  • [7] Ifosfamide salvage treatment before autologous stem cell transplantation in patients with refractory and relapsed Hodgkin's lymphoma:: a GELA experience
    Gisselbrecht, C
    Mounier, N
    Fermé, C
    Brice, P
    ANNALS OF ONCOLOGY, 2003, 14 : 39 - 41
  • [8] IIVP regimen for salvage therapy in patients with relapsed lymphoma prior to autologous stem cell transplantation.
    Abali, H
    Karaoglu, A
    Tekuzman, G
    Koc, Y
    Kansu, E
    BLOOD, 2001, 98 (11) : 389B - 389B
  • [9] Autologous stem cell transplantation for children and adolescents with relapsed and refractory Hodgkin's lymphoma
    Asl, A. Hedayati
    Mehrvar, A.
    Zangooei, R.
    Faranoush, M.
    Dinarooni, P.
    Olad, E.
    Jenabzadeh, M.
    Athari, G.
    Fallah, V
    Haghighi, M.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S277 - S277
  • [10] Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma
    Colpo, Anna
    Hochberg, Ephraim
    Chen, Yi-Bin
    ONCOLOGIST, 2012, 17 (01): : 80 - 90